Holen Sie sich die Stockscreener-App
11.02
0.46%
0.05
Handel nachbörslich:
11.02
Certara Inc Aktie (CERT) Neueste Nachrichten
What makes Certara Inc. stock price move sharplyJuly 2025 News Drivers & Accurate Buy Signal Alerts - sundaytimes.kr
Shareholders Will Be Pleased With The Quality of Certara's (NASDAQ:CERT) Earnings - simplywall.st
Certara’s SWOT analysis: biosimulation firm’s stock faces growth hurdles By Investing.com - Investing.com Canada
Certara’s SWOT analysis: biosimulation firm’s stock faces growth hurdles - Investing.com
Certara (CERT) Is Up 9.0% After Simcyp Simulator Wins EMA Qualification and Q2 Sales Rise—Has the Bull Case Changed? - simplywall.st
Certara Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Certara, Inc. Reports Strong Q2 2025 Earnings Growth - TipRanks
Certara, Inc. Reports Strong Q2 2025 Growth - TipRanks
Here's Why It's Unlikely That Certara, Inc.'s (NASDAQ:CERT) CEO Will See A Pay Rise This Year - 富途牛牛
Can Traders Expect Breakout From Certara Inc. This WeekLow Capital High Return Stock Plans Reviewed - beatles.ru
Certara signals full year 8–10% revenue growth outlook as AI and QSP momentum builds - MSN
Certara, Inc. (NASDAQ:CERT) Q2 2025 Earnings Call Transcript - Insider Monkey
Certara's Financials Obscure Share Price Momentum: What's Next? - AInvest
Certara, Inc.'s (NASDAQ:CERT) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - Yahoo Finance
Certara, Inc. (CERT) Q2 Earnings Miss Estimates - MSN
Certara 2025 Q2 Earnings Narrows Losses, Reports 84.3% Reduction in Net Loss - AInvest
Navigator Holdings Ltd. shares fall 1.00% intraday after Certara, Inc. reports Q2 2025 earnings. - AInvest
Certara, Inc. (CERT): A Bull Case Theory - Insider Monkey
UBS Maintains Certara (CERT) Rating, Lowers Price Target to $15. - GuruFocus
Leerink Partners lowers Certara stock price target to $11.50 on valuation concerns By Investing.com - Investing.com South Africa
Leerink Partners lowers Certara stock price target to $11.50 on valuation concerns - Investing.com Nigeria
Certara Surges 15.58% Amid Volatile Intraday Action—What’s Fueling the Rally? - AInvest
UBS Adjusts Price Target on Certara to $15 From $17.50, Maintains Buy Rating - MarketScreener
Earnings call transcript: Certara misses Q2 2025 EPS forecast, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Certara misses Q2 2025 EPS forecast, stock dips - Investing.com
Certara’s Mixed Signals: Hold Rating Amidst Growth Potential and Strategic Uncertainty - TipRanks
Certara's Q2 Results and Strategic Positioning Support Buy Rating with $16 Price Target - AInvest
Certara (CERT) Q2 Revenue Jumps 12% - AOL.com
Decoding Certara Inc (CERT): A Strategic SWOT Insight - GuruFocus
Certara's AI-Driven Biosimulation Platform: A Catalyst for Drug Development Transformation - AInvest
Certara's Q2 2025 Earnings: Strategic Resilience in a Shifting Biosimulation Landscape - AInvest
Certara's Q2 2025 Earnings Call: Contradictory Signals on Market Potential, Demand Dynamics, and Retention Rates - AInvest
Certara Expects Full-Year Revenue Growth of 8-10% on AI, QSP Momentum - AInvest
Certara Grows In Q2 But Falls Short Of Analyst Estimates - Finimize
Certara Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Press Release: Certara Reports Second Quarter 2025 Financial Results - 富途牛牛
Certara Q2 2025 slides: 12% revenue growth despite swing to net loss By Investing.com - Investing.com South Africa
Certara Q2 adjusted EPS misses estimates - MarketScreener
Certara Q2 2025 slides: 12% revenue growth despite swing to net loss - Investing.com UK
CERT SEC FilingsCertara, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Certara Earnings: Software Revenue Surges 22% as Biosimulation Demand Drives Record Q2 Performance - Stock Titan
Visual analytics tools that track Certara Inc. performanceSwing Reversal Forecast Based on Patterns - Newser
Navigator Holdings Ltd. shares rise 1.84% intraday after Certara's Simcyp Simulator receives EMA qualification. - AInvest
The PBPK Revolution: How Certara's Simcyp Simulator is Reshaping Drug Development and Regulatory Acceptance - AInvest
Certara Simcyp Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling - MarketScreener
Certara Obtains European Medicines Agency Qualification for Biosimulation Software - MarketScreener
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling - The Manila Times
Certara's Simcyp® Simulator Achieves EMA Qualification for Regulatory Submissions in the EU - Quiver Quantitative
Certara - Via Ritzau
Why is Certara Inc. stock attracting strong analyst attentionUnlock daily market insights for better trades - Jammu Links News
What institutional investors are buying Certara Inc. stockUnlock powerful portfolio optimization tools - Jammu Links News
What markets is Certara Inc. expanding into Is KREF stock a good long term investment optionExceptional profit potential - Jammu Links News
What are analysts’ price targets for Certara Inc. in the next 12 monthsBreakthrough financial growth - Jammu Links News
What is the risk reward ratio of investing in Certara Inc. stockNavigate market volatility with smart strategies - Jammu Links News
How strong is Certara Inc. company’s balance sheetFree Expert Stock Watchlist - Jammu Links News
What catalysts could drive Certara Inc. stock higher in 2025Dynamic growth stocks - Jammu Links News
2.70%
7.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):